BS Summary: This article contains 6 faulty reasoning types, including Negativity Bias, Loss Aversion, and Availability Heuristic, with Attempt to Sell a Product or Service as the most egregious example at 21.6% saturation with 61 hits. Analysis detected 202 faulty-reasoning hits from 282 analyzed words, generating a BS Score of 41% and a BS Rank of 31% (10,271 of 14,814 articles). This article is better (less manipulative) than 69.30% of the article peer group.
AstraZeneca, Ionis report major trial failure with heart disease drug
The drug didn’t outperform placebo in a condition known as ATTR-CM
Europe Correspondent
Andrew covers the biopharma industry, scientific research, and public health across the continent.
You can reach Andrew confidentially on Signal at drewqjoseph.71.
LONDON — In a blow to its cardiovascular aspirations, AstraZeneca said Thursday that its drug for a heart disease — one that has become an increasingly competitive target for biopharma companies — failed in a pivotal trial.
The drug, called Wainua, on which AstraZeneca is partnered with Ionis Pharmaceuticals, did not outperform placebo in reducing cardiovascular death and clinical events for patients with a condition known as ATTR-CM, or transthyretin-mediated amyloid cardiomyopathy.
AstraZeneca’s U.S. shares were down some 8% in premarket trading, while its London-listed shares were down 9% early Thursday.
Ionis shares, meanwhile, were down 12% in premarket hours.
STAT+ Exclusive Story
Already have an account?
Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Totals $468 per year
for 3 months, then $399/year
Savings start at 25%!
$300 Annually per user
To read the rest of this story subscribe to STAT+.
cardiology , drug development , Pharmaceuticals , STAT+
Submit a correction request Reprints
STAT Plus: Roche ends Huntington’s gene-silencing programs
STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs
STAT Plus: Prime wins Beam arbitration, clearing path to clinic
Adam's Biotech Scorecard
STAT Plus: 931 days.
The drug approval scandal hiding in plain sight
STAT Plus: The quest to save Grace — and clear the way for rare disease patients everywhere
Speakers
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.